Indivior CEO looks beyond 2015 after troubled Reckitt pharma unit's spinoff; Novo searching for new CEO with Sørensen out as soon as next year;

> Indivior CEO looks beyond 2015 after troubled Reckitt pharma unit's spinoff. Editor's Corner

> Novo searching for new CEO with Sørensen out as soon as next year. More

> Roche builds CLL case for Gazyva in two-horse race with GSK. Article

> Actavis goes 1-for-2 with FDA as regulators knock blood pressure combo. Story

> Sen. Warren urges CMS to get on board, encourage UDI info in insurance claims forms. News

Suggested Articles

Genentech followed a $1 billion pact with Sosei Heptares with discovery deals around cancer and neurological diseases with Skyhawk and Convelo.

The partners will use wearable devices to assess how heart failure patients function and feel after being discharged from hospitals.

After spinning out two companies at the start of the year, Sosei Heptares has now inked a new deal with Roche biologics unit Genentech.